Essential Premium

Seligman Cuts AI Exposure, Preserving a Nearly 40 Percent Gain

Paul Wick’s tech-focused hedge fund trimmed AI winners before the summer correction, making the fund one of the year’s top performers.

2026 TraderForum Equity Trading Summit

November 10-11, 2026 | Loews Coral Gables Hotel

Investors Are Underpricing AI’s Political Risk, Xponance Warns

The investment case for the AI buildout, including data centers, is strong, but so are the constraints, says Tina Byles Williams.

Sponsored

Is the S&P 500's Concentrated Rally Starting to Diversify?

2026 Hedge Fund Roundtable | The AI Opportunity Through a Hedge Fund Lens

From Equitizing Cash to Core Holdings: How Asset Owners are Rethinking ETFs

AI Drug Discovery Reaches the IPO Market

Iambic Therapeutics, backed by Coatue, Nvidia, Millennium, and Two Sigma, is bringing its AI-based drug development to public investors.

Related Content

Seligman’s AI Winners ‘Carry the Fund’

Stephen Taub

July Was the Month the Crowded AI Trade Reversed

The Editorial Team

Commonfund Remains Optimistic About Equities, But Warns AI Boom Will Slow

James Comtois

2026 TraderForum LatAm Conference

November 11-12, 2026 | Loews Coral Gables Hotel

1270 Avenue of the Americas, Suite 1100

New York, NY 10020

 

© Institutional Investor, LLC. All material subject to strictly enforced copyright laws. Please read our Terms and Conditions and Privacy Policy before using the site. Institutional Investor is part of Delinian.

 

| Unsubscribe

LinkedIn
X (Twitter)
Bluesky
Instagram